153 related articles for article (PubMed ID: 8121319)
21. [Digital blood flow in peripheral vascular diseases. Action of drugs: buflomedil].
Frausini G; Rotatori P; Gaggi S; Barone A; Pupita F
Minerva Cardioangiol; 1988 Jun; 36(6):319-22. PubMed ID: 3211330
[No Abstract] [Full Text] [Related]
22. [Treatment of frostbites. Analysis of results in twenty patients with buflomedil chlorhydrate (author's transl)].
Foray J; Baisse PE; Mont JP; Cahen C
Sem Hop; 1980 Mar 8-15; 56(9-10):490-7. PubMed ID: 6244676
[TBL] [Abstract][Full Text] [Related]
23. [Effectiveness of buflomedil in arterial occlusive disease. Modification of transcutaneous oxygen pressure in a placebo-controlled double-blind study].
Sunder-Plassmann L; Gandolfo AM; Utz C
MMW Munch Med Wochenschr; 1984 Mar; 126(9):247-8. PubMed ID: 6425678
[No Abstract] [Full Text] [Related]
24. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
Mellouli F; Bejaoui M
Arch Pediatr; 2008 Jan; 15(1):24-8. PubMed ID: 18164913
[TBL] [Abstract][Full Text] [Related]
25. Normal sublingual microcirculation during painful crisis in sickle cell disease.
van Beers EJ; Goedhart PT; Unger M; Biemond BJ; Ince C
Microvasc Res; 2008 May; 76(1):57-60. PubMed ID: 18423765
[TBL] [Abstract][Full Text] [Related]
26. The influence of Emla cream on cutaneous microcirculation.
Häfner HM; Thomma SR; Eichner M; Steins A; Jünger M
Clin Hemorheol Microcirc; 2003; 28(3):121-8. PubMed ID: 12775894
[TBL] [Abstract][Full Text] [Related]
27. Dialysis clearance of buflomedil in hemodialysed patients.
Rey E; Moynot A; d'Athis P; Pello JY; Maurel A; Frydman MO; Buisson C; Olive G
Arzneimittelforschung; 1996 May; 46(5):492-5. PubMed ID: 8737633
[TBL] [Abstract][Full Text] [Related]
28. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial.
Erbs S; Linke A; Schächinger V; Assmus B; Thiele H; Diederich KW; Hoffmann C; Dimmeler S; Tonn T; Hambrecht R; Zeiher AM; Schuler G
Circulation; 2007 Jul; 116(4):366-74. PubMed ID: 17620510
[TBL] [Abstract][Full Text] [Related]
29. [Whole blood filterability in chronic cerebrovascular disorders: effects of the use of buflomedil hydrochloride].
Ciuffetti G; Mercuri M; Lombardini R; Palazzetti D; Rizzo MT; Parnetti L
Minerva Med; 1989 Nov; 80(11):1237-40. PubMed ID: 2689916
[TBL] [Abstract][Full Text] [Related]
30. Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease.
Kopecky EA; Jacobson S; Joshi P; Koren G
Clin Pharmacol Ther; 2004 Mar; 75(3):140-6. PubMed ID: 15001964
[TBL] [Abstract][Full Text] [Related]
31. [The use of buflomedil in the treatment of post-traumatic cerebral edema].
Urciuoli R; Reggio S
Agressologie; 1988 May; 29(6):469-71. PubMed ID: 3213896
[No Abstract] [Full Text] [Related]
32. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
Koc A; Gumruk F; Gurgey A
Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
[TBL] [Abstract][Full Text] [Related]
33. Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: computer-assisted intravital microscopy study.
Cheung AT; Chan MS; Ramanujam S; Rangaswami A; Curl K; Franklin P; Wun T
J Investig Med; 2004 Sep; 52(6):402-6. PubMed ID: 15612454
[TBL] [Abstract][Full Text] [Related]
34. [Effect of the vasoactive drug buflomedil in arterial occlusive disease].
Racenberg J; Intaglietta M; Messmer K
Fortschr Med; 1982 Nov; 100(41):1926-30. PubMed ID: 7152426
[TBL] [Abstract][Full Text] [Related]
35. [Protective effect of buflomedil hydrochloride on erythrocyte sickling. In vitro study].
Briguglio F; Briguglio E; Di Marco V
Minerva Med; 1986 Feb; 77(7-8):249-62. PubMed ID: 3951731
[TBL] [Abstract][Full Text] [Related]
36. Effects of buflomedil in a group of patients with chronic peripheral arterial diseases. Clinical and hemorheological evaluation.
Mozzi E; Chiurazzi D; Spinola A; Annoni F; Germiniani R
J Int Med Res; 1985; 13(6):317-21. PubMed ID: 4076530
[TBL] [Abstract][Full Text] [Related]
37. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial.
van Beers EJ; van Tuijn CF; Nieuwkerk PT; Friederich PW; Vranken JH; Biemond BJ
Am J Hematol; 2007 Nov; 82(11):955-60. PubMed ID: 17617790
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous microvascular effects of mid-term hormone replacement therapy in healthy postmenopausal women: a prospective placebo controlled trial.
Chabbert-Buffet N; Bonnin P; Lévy B; Abdoucheli-Baudot N; Tribout L; Gaitz JP; Vayssairat M
J Mal Vasc; 2003 Oct; 28(4):190-3. PubMed ID: 14618108
[TBL] [Abstract][Full Text] [Related]
39. Cytokine profile of sickle cell disease in Oman.
Pathare A; Al Kindi S; Alnaqdy AA; Daar S; Knox-Macaulay H; Dennison D
Am J Hematol; 2004 Dec; 77(4):323-8. PubMed ID: 15551290
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of reticulated platelets in patients with sickle cell diseases.
Noronha JF; Costa FF; Saad ST; Lorand-Metze IG; Grotto HZ
Thromb Res; 2007; 121(2):259-67. PubMed ID: 17521711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
